Every Form 4 that Mannkind Corporation (MNKD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MNKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNKD filings page.
MannKind Corp. director Steven B. Binder sold 39,051 shares of common stock on September 25, 2026, at a weighted average price of $3.29 per share. The sale was made under a Rule 10b5-1 plan established December 2, 2025; Binder directly held 713,258 shares after the transaction.
MANNKIND CORP (MNKD) director Steven B. Binder reported selling 33,558 shares$3.81 per share752,309 shares
MannKind Corp director Steven B. Binder reported selling 39,051 shares of common stock on 2026-08-07 in an open-market transaction under a pre-established Rule 10b5-1 trading plan. The weighted average sale price was $4.06 per share, and Binder now directly holds 785,867 shares of MannKind common stock.
MANNKIND CORP Chief Financial Officer Christopher B. Prentiss reported two tax-withholding dispositions of common stock on July 15, 2026, totaling 22,247 shares at $4.09 per share. The shares were delivered or withheld to satisfy exercise price or tax liabilities upon vesting of previously reported restricted stock units under Rule 16b-3. His reported direct holdings include 1,991 shares acquired through the Employee Stock Purchase Plan on June 30, 2026.
MannKind Corp reports that Dominic Marasco, President of the Endocrine Business Unit, had 3,623 shares of common stock withheld on July 15, 2026 at $4.09 per share as a tax-withholding disposition related to the vesting of previously reported restricted stock units under Rule 16b-3. Following this transaction, he directly holds 343,398 shares, including 2,775 shares acquired through the Employee Stock Purchase Plan on June 30, 2026.
MannKind Corp Chief People & Workpl Officer Stuart A. Tross had a previously granted performance restricted stock unit award vest on July 15, 2026, delivering 93,790 shares of common stock. To cover taxes, a total of 65,808 shares were withheld at $4.09 per share, and his direct holdings include shares acquired through the Employee Stock Purchase Plan.
MannKind Corp reports that CEO Michael Castagna had a performance-based restricted stock unit award granted on May 25, 2023 vest on July 15, 2026, delivering 350,260 common shares after achieving 83% of target performance. The original 422,000-unit grant left 71,740 units forfeited. On the same date, an aggregate 363,200 shares of common stock were withheld or delivered at $4.09 per share to satisfy exercise price or tax obligations related to equity awards.
MannKind Corp EVP Technical Operations Sanjay R. Singh reported vesting of a performance-based restricted stock unit award granted in May 2023, delivering 70,550 common shares on July 15, 2026. Footnotes state performance goals were achieved at 83% of target, with 14,450 units forfeited. To satisfy tax obligations, 46,795 shares were withheld at $4.09 per share and characterized as payments of tax liability by delivering or withholding shares under Rule 16b-3. Each restricted stock unit represented one share of common stock.
David Thomson, EVP, General Counsel & Secretary of MannKind, acquired 93,790 shares of common stock on July 15, 2026 through vesting of a performance RSU award, while 19,210 shares were forfeited under the plan. To cover taxes, 98,426 shares were withheld at about $4.09 per share. On July 17, he sold 24,109 shares at a weighted average of $4.05 under a Rule 10b5-1 plan established December 2, 2025, leaving 797,554 shares held directly.
MannKind Corp director Steven B. Binder reported multiple equity transactions. On July 15, 2026, a performance RSU award granted in 2023 vested at 83% of target, delivering 93,790 shares and forfeiting 19,210. Shares totaling 24,395 were withheld to cover taxes. On July 17, 2026, he sold 52,485 shares of common stock at a weighted average price of $4.06, in open-market transactions under a Rule 10b5-1 plan established December 2, 2025. After these transactions, he directly holds 824,918 shares of MannKind common stock.
Friedman Michael A reported acquisition or exercise transactions in this Form 4 filing.
MANNKIND CORP director Michael A. Friedman reported a grant and vesting of 82,781 restricted stock units (RSUs) tied to the company’s common stock. Each RSU represents a contingent right to receive one share of MannKind common stock. The RSUs vested on May 20, 2026, but the underlying shares will only be delivered after Friedman separates from service on the MannKind board of directors. Following this award, he holds 82,781 RSUs directly.
MannKind Corporation director Ronald J. Consiglio reported equity compensation and a share purchase tied to his board service. He acquired 10,000 shares of common stock at $2.95 per share through the company’s Market Price Stock Purchase Plan, which was approved by the board on May 20, 2026.
He also received two awards of restricted stock units (RSUs) covering 16,556 and 82,781 units. Each RSU represents a contingent right to receive one share of MNKD common stock, with shares generally delivered only after separation from the board. Following these transactions, he directly holds 132,342 common shares. Footnotes note that 423,655 deferred RSUs were inadvertently included in prior reported share holdings.
Binder Steven B. reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corporation director Steven B. Binder reported receiving a grant of restricted stock units under the company’s equity compensation program. He was awarded 82,781 restricted stock units, each representing a contingent right to receive one share of MannKind common stock.
The filing notes that these restricted stock units vested on May 20, 2026, but the underlying shares will not be delivered until Binder experiences a separation of service from MannKind’s board of directors. After this grant, he holds 82,781 restricted stock units directly, highlighting a compensation-related equity award rather than an open-market share purchase or sale.
Grancio Jennifer reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corp director Jennifer Grancio reported a compensation-related equity award and updated holdings. She received a grant of 82,781 restricted stock units, each representing a contingent right to receive one share of MannKind common stock.
The restricted stock units vested on May 20, 2026, but the underlying shares will only be delivered after her separation of service from MannKind’s board of directors. Following the reported transactions, she holds 110,701 shares of common stock directly, alongside the newly granted 82,781 restricted stock units. A footnote also clarifies that 134,114 shares representing deferred restricted stock units had been inadvertently included in prior reported common stock holdings.
MannKind Corporation director Anthony C. Hooper reported equity-based compensation in the form of restricted stock units (RSUs). On May 20, 2026, he received an award of 16,556 RSUs, each representing a contingent right to one share of MannKind common stock, which vested that day but will only be delivered after he separates from the board.
On the same date, he also received a second grant of 82,781 RSUs in lieu of his annual cash retainer as a non-employee director. This award vests immediately, with share delivery likewise deferred until his separation from board service. These are compensation-related acquisitions, not open-market purchases or sales of MannKind shares.
Shannon James Samuel reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corporation director James Samuel Shannon reported new equity awards and updated his share holdings. The filing shows he holds 36,458 shares of MannKind common stock directly. He also received two grants of restricted stock units (RSUs) tied to MannKind common stock.
One RSU grant covers 16,556 units that vested on May 20, 2026, but the underlying shares will only be delivered after he separates from service on MannKind’s board. A second grant of 82,781 RSUs was awarded in lieu of an annual cash retainer for non‑employee directors and vests immediately, with share delivery also deferred until board service ends. Each RSU represents the right to receive one share of MannKind common stock.
MANNKIND CORP Chief People & Workpl Officer Stuart A. Tross reported acquiring 33,898 shares of common stock at $2.95 per share. The shares were purchased through the company’s Market Price Stock Purchase Plan, which was approved by the Board of Directors on May 20, 2026. Following this transaction, he directly owns 1,026,122 common shares.
MannKind Corp executive Dominic Marasco, President of the Endocrine Business Unit, reported an acquisition of company stock through a compensation-related plan. He received 8,474 shares of common stock at $2.95 per share under the issuer's Market Price Stock Purchase Plan, which was approved by the board on May 20, 2026. Following this award, his directly held position increased to 344,246 shares of common stock, which includes 2,343 shares acquired under the issuer's Employee Stock Purchase Plan on December 31, 2025.
MUNDKUR CHRISTINE reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corp director Christine Mundkur reported a new equity award and clarified prior holdings. She received a grant of 82,781 restricted stock units, each representing a contingent right to receive one share of MannKind common stock.
The restricted stock units vested on May 20, 2026, but the underlying shares will not be delivered until she separates from service on MannKind’s board of directors. Following the reported activity, she directly holds 27,675 shares of MannKind common stock. A footnote states that 226,818 shares representing deferred restricted stock units were inadvertently included in earlier reported common stock holdings.
Kay Sabrina reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corporation director Sabrina Kay reported a compensation-related stock award rather than an open-market trade. On May 20, 2026, she received a grant of 82,781 restricted stock units (RSUs), each representing a contingent right to one share of MannKind common stock. The RSU grant is shown with a price of $0.0000 per unit, reflecting that it is an award, not a purchase. The filing also shows she holds 107,033 shares of common stock directly after the reported transactions and 82,781 RSUs outstanding. A footnote explains that 158,567 shares representing deferred restricted stock units had been inadvertently included in prior common-stock holdings and are now correctly reflected as deferred RSUs.
MANNKIND CORP Chief People & Workplace Officer Stuart A. Tross reported a routine tax-related share disposition. On the vesting of restricted stock units originally granted on May 10, 2022, 8,073 shares of common stock were withheld to cover tax withholding obligations at a value of $3.52 per share. After this non-market transaction, Tross directly holds 992,224 shares of MANNKIND CORP common stock.
MannKind Corp director Steven B. Binder reported an open-market sale of 16,940 shares of common stock at a weighted average price of $3.29 per share on May 12, 2026, executed under a Rule 10B5-1 trading plan established on December 2, 2025.
Binder also had 5,560 shares withheld on May 11, 2026 to cover tax obligations arising from the vesting of restricted stock units originally granted on May 10, 2022. Following these transactions, he directly holds 808,008 MannKind shares.
MANNKIND CORP Chief Executive Officer Michael Castagna reported a routine share withholding related to taxes on vested equity. On May 11, 34,957 shares of common stock were withheld at $3.52 per share to satisfy tax withholding obligations from Restricted Stock Units originally granted on May 10, 2022.
These shares were not sold in the open market but used to cover taxes due at vesting. After this transaction, Castagna directly holds 2,442,310 shares of MannKind common stock, which includes 1,356 shares acquired under the company’s Employee Stock Purchase Plan on December 31, 2025.
MannKind Corp executive David Thomson, EVP, General Counsel & Secretary, reported recent transactions in the company’s common stock. He completed an open-market sale of 3,033 shares at a weighted average price of $3.29 per share, executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on August 27, 2025. Separately, 12,387 shares were withheld to cover tax obligations tied to the vesting of restricted stock units that were originally granted on May 10, 2022, which is a non-market, tax-related disposition. After these transactions, Thomson directly holds 826,299 shares of MannKind common stock.
MANNKIND CORP Chief Executive Officer Michael Castagna filed an amended insider report clarifying that a previously filed Form 4 was erroneous. The earlier Form 4 had mistakenly shown him directly acquiring 100,000 MannKind common shares on March 10, 2026.
The amendment explains these shares were actually acquired by his spouse in a segregated retirement account in which he has no pecuniary interest, so the transaction should not be attributed to him and the prior Form 4 should be deemed revoked. As of March 10, 2026, he is reported as directly owning 2,475,911 MannKind common shares.
MannKind Corp Chief Financial Officer Christopher B. Prentiss reported a routine tax-withholding share disposition. On April 22, 2026, 12,267 shares of common stock at $2.74 per share were withheld to cover taxes on Restricted Stock Units that vested from a grant dated May 15, 2024. After this, he directly held 338,924 shares, including 2,337 shares acquired through the Employee Stock Purchase Plan on December 31, 2025.
MannKind Corp’s Chief Financial Officer Christopher B. Prentiss received new equity awards. He was granted 221,000 performance-based restricted stock units, each representing a right to one share of common stock, and 217,000 employee stock options with a $2.44 exercise price, all held directly.
The performance units vest on January 15, 2029, with actual payout from 0% to 300% of the 221,000-share target based on MannKind’s total shareholder return from April 1, 2026 through December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index. The options vest 25% on March 23, 2027 and then 1/16 quarterly until fully vested, and expire on March 23, 2036.
MannKind Corp Chief Executive Officer Michael Castagna received new equity compensation awards. He was granted 796,000 performance-based restricted stock units, each representing the right to receive one share of common stock. The actual shares that vest on January 15, 2029 can range from 0% to 300% of this target, based on MannKind’s total shareholder return from April 1, 2026 to December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index.
He was also granted stock options for 782,000 shares of common stock at an exercise price of $2.4400 per share, expiring on March 23, 2036. These options vest 25% on March 23, 2027 and the remaining portion in equal quarterly installments over four years.
MannKind Corp reported new equity awards for EVP Technical Operations Sanjay R. Singh. He received 221,000 performance-based restricted stock units, each tied to one common share, that vest on January 15, 2029 with payout ranging from 0% to 300% of target based on relative total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028. He was also granted options on 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and the remainder in equal quarterly installments through 2031, expiring March 23, 2036. These are compensation-related grants, not open-market trades.
MannKind Corporation’s Chief Medical Officer, Ajay Ahuja, reported new equity awards. He received 221,000 performance-based restricted stock units, each representing a right to one share of common stock. These units vest on January 15, 2029, with the actual payout ranging from 0% to 300% of the target based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028.
He was also granted options on 217,000 shares of common stock at an exercise price of $2.44 per share. These options vest 25% on March 23, 2027, with the remaining 75% vesting in 1/16th increments quarterly, and expire on March 23, 2036. All positions are held directly and reflect compensation awards rather than market purchases or sales.
MannKind Corp granted Chief People & Workplace Officer Stuart A. Tross new equity awards. He received 221,000 performance-based restricted stock units, each representing the right to one share of common stock. These units vest on January 15, 2029, with the payout from 0% to 300% of target based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028.
He was also granted 217,000 stock options with a $2.44 exercise price, expiring on March 23, 2036. These options vest 25% on March 23, 2027, with the remaining 75% vesting in equal quarterly installments over four years.
MannKind Corp EVP and General Counsel David Thomson reported equity awards, not open-market trades. He received 221,000 performance-based restricted stock units, each representing a contingent right to one share of common stock.
The performance units vest on January 15, 2029, with payout tied to MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 to December 31, 2028. Payout ranges from 0% to 300% of the 221,000-target based on percentile rankings.
Thomson was also granted stock options for 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and then 1/16 quarterly through March 23, 2031.
MannKind Corp CEO Michael Castagna purchased 100,000 shares of common stock in an open-market transaction at a weighted average price of $2.59 per share on March 10, 2026. Following this purchase, he directly owns 2,575,911 shares. An additional 1,500 shares are held indirectly through his spouse.
MannKind Corp director Shannon James Samuel acquired 12,000 shares of common stock at a price of $3.27 per share. The acquisition was made through the company’s Market Price Stock Purchase Plan, which was approved by the Board of Directors on March 1, 2026.
Following this grant or award acquisition, Samuel’s direct holdings increased to 64,635 shares of MannKind common stock. This transaction reflects participation in a board-approved stock purchase plan rather than an open-market trading decision.
MannKind Corp director Anthony C. Hooper acquired 35,000 shares of common stock on March 1, 2026 at a price of $3.27 per share. The shares were purchased through the company’s Market Price Stock Purchase Plan, which was approved by the board on that date. Following this transaction, Hooper directly owns 236,153 MannKind shares.
MannKind Corp's Chief Financial Officer Christopher B. Prentiss acquired additional company stock through a board-approved purchase plan. On March 1, 2026, he obtained 5,000 shares of common stock at $3.27 per share under the Market Price Stock Purchase Plan. Following this transaction, he directly owned 348,854 shares of MannKind common stock.
MannKind Corp Chief Executive Officer Michael Castagna reported multiple share and option acquisitions. On March 1, 2026, he acquired 15,290 shares of common stock at $3.27 per share through the company’s Market Price Stock Purchase Plan, which was approved by the board.
Following this, his direct common stock holdings rose to 2,475,911 shares. On February 26, 2026, performance milestones were reached for stock options originally granted in 2016 and 2017, leading to partial vesting of options covering 50,000, 57,750, and 37,525 shares, increasing his directly held option awards.
MannKind Corp director Steven B. Binder reported the vesting of performance-based stock options. On February 26, 2026, a defined performance milestone was achieved under an option originally granted on August 24, 2017, resulting in a grant-credited acquisition of 45,025 employee stock options at an exercise price of $0.00 per option.
Thomson David reported acquisition or exercise transactions in this Form 4 filing.
MannKind Corp executive David Thomson reported new option vesting tied to performance goals. On February 26, 2026, 20,000 and 37,525 employee stock options (rights to buy shares) became partially vested from grants originally awarded in 2016 and 2017 after defined performance milestones were achieved.
MannKind Corp executive Stuart A. Tross reported acquisitions of both stock and options. He obtained 15,290 shares of common stock at $3.27 per share through MannKind’s Market Price Stock Purchase Plan, bringing his direct holdings to 1,000,297 common shares. He also acquired stock options for 20,000 and 28,143 shares after performance milestones from 2017 option grants were met on February 26, 2026, resulting in partial vesting of those awards.
MannKind Corporation reported an insider stock sale by Chief People & Workplace Officer Stuart A. Tross. On January 8, 2026, he sold 47,006 shares of MannKind common stock at a price of $6.33 per share. After this transaction, he continued to beneficially own 985,007 shares of common stock in direct ownership form. The filing notes that the sale occurred pursuant to a pre-established Rule 10b5-1 trading plan that was put in place on June 17, 2025, indicating the trades were scheduled in advance.
MannKind Corp Chief Executive Officer and director Michael Castagna reported stock option exercises and related share sales in recent insider transactions. On 12/12/2025 he exercised 20,806 employee stock options at $4.55 per share and sold 20,806 shares of common stock at $6, leaving him with 2,504,792 common shares held directly. On 12/16/2025 he exercised a further 21,310 options at $4.55 and sold 21,310 common shares at $6, again ending with 2,504,792 directly held shares. Following these trades, he beneficially owns 15,804 employee stock options with a $4.55 exercise price expiring on 05/19/2026. The transactions were carried out under a Rule 10b5-1 trading plan established on August 8, 2025.
MannKind Corporation executive reports stock sale under pre-set plan. On 11/14/2025, an officer of MannKind Corp (MNKD), serving as EVP Technical Operations, sold 18,777 shares of common stock in an open-market transaction coded as a sale. The weighted average sale price was $5.03 per share, based on individual trades between $5.00 and $5.07. After this transaction, the executive directly beneficially owned 455,211 shares of MannKind common stock. The filing notes that the sale occurred pursuant to a Rule 10b5-1 trading plan that was established on May 14, 2025, indicating the trades were made according to a pre-arranged schedule.
MannKind (MNKD) filed a Form 4 showing its Chief Medical Officer acquired 318,200 shares of common stock via restricted stock units on 11/11/2025 at a price of $0. Following the grant, the reporting person beneficially owned 318,200 shares, held directly.
The RSUs carry a four-year vesting schedule: no shares vest on the first anniversary of the vesting determination date of September 29, 2025, and one-third vests on each anniversary thereafter until fully vested on the fourth anniversary.
MannKind Corp (MNKD) reported an insider Form 4 for its EVP of Technical Operations. On 10/31/2025, the company withheld 17,071 shares of common stock in a transaction coded F, reflecting shares retained by the issuer to cover taxes upon vesting of previously reported RSUs at a price of $5.59 per share.
Following this tax-withholding event, the reporting person directly beneficially owns 473,988 shares of MannKind common stock.